ONMDW · Insider Trading
OneMedNet Corp Warrant
Every open-market purchase and sale reported by ONMDW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Jeffrey Yu | Chief Medical Officer | Buy | +172,414 | +$100.00K |
| 2026-06-16 | Aaron Green | Chief Executive Officer | Buy | +55,622 | +$30.70K |
| 2026-06-15 | Thomas Kosasa | Director | Buy | +158,730 | +$100.00K |
| 2026-05-20 | Thomas Kosasa | Director | Buy | +268,817 | +$250.00K |
| 2026-04-24 | Jeffrey Yu | Chief Medical Officer | MIXED | +1,123,043 | +$932.13K |
| 2026-04-24 | Thomas Kosasa | Director | Buy | +876,136 | +$750.00K |
| 2025-12-23 | Aaron Green | Chief Executive Officer | Sell | −126,322 | −$218.62K |
| 2025-11-26 | Kenneth Alleyne | Director | A | +38,219 | — |
| 2025-11-26 | Jair Clarke | Director | A | +138,485 | — |
| 2025-11-26 | Aaron Green | Chief Executive Officer | MIXED | +1,330,425 | +$274.08K |
| 2025-11-26 | Robert Lawrence Golden | Chief Financial Officer | MIXED | +547,905 | +$513 |
| 2025-11-26 | Jeffrey Yu | Chief Medical Officer | MIXED | +67,762 | +$17.19K |
| 2025-11-26 | Sherry Coonse McCraw | Director | A | +56,342 | — |
| 2025-11-26 | Eric Casaburi | Director | MIXED | +110,475 | +$39.26K |
| 2025-11-26 | Andrew B Zeinfeld | Director | A | +144,403 | — |
| 2025-11-26 | Thomas Kosasa | Director | MIXED | +7,451,367 | +$5.24M |
| 2025-11-26 | Jeffrey Yu | Chief Medical Officer | MIXED | +4,563,028 | +$2.80M |
| 2025-11-26 | Jeffrey Yu | Chief Medical Officer | MIXED | +240,309 | +$140.47K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Thomas Kosasa | Director | 17,088,874 | $510.96K |
| Jeffrey Yu | Chief Medical Officer | 9,933,650 | $297.02K |
| Aaron Green | Chief Executive Officer | 1,859,725 | $55.61K |
| Robert Lawrence Golden | Chief Financial Officer | 469,572 | $14.04K |
| Andrew B Zeinfeld | Director | 254,382 | $7.61K |
| Jair Clarke | Director | 138,485 | $4.14K |
| Eric Casaburi | Director | 65,475 | $1.96K |
| Kenneth Alleyne | Director | 38,219 | $1.14K |
| Sherry Coonse McCraw | Director | 11,342 | $339 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ONMDW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.